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ABSTRACT 
The present study was aimed to investigate the effect of microneedle (MN) geometry 
parameters like length, density, shape and type on transdermal permeation enhancement of 
Amlodipine (AMLO). Two types of MN devices viz. AdminPatch® arrays (ADM) (0.6, 1.2 
and 1.5 mm lengths) and laboratory fabricated polymeric MNs (PM) of 0.6 mm length were 
employed.  In the case of PMs, arrays were applied thrice at different places within a 1.77cm2 
skin area (PM-3) to maintain the MN density closer to 0.6 mm ADM. Scaling analyses was 
done using dimensionless parameters like concentration of AMLO (Ct/Cs), thickness (h/L) 
and surface area of the skin (Sa/L2). Micro-injection moulding technique was employed to 
fabricate PM. Histological studies revealed that the PM, owing to their geometry/design, 
formed wider and deeper microconduits when compared to ADM of similar length. 
Approximately 6.84 and 6.11 fold increase in the cumulative amount (48 h) of AMLO 
permeated was observed with 1.5 mm ADM and PM-3 treatments respectively, when 
compared to passive permeation amounts. Good correlations (R2 > 0.89) were observed 
between different dimensionless parameters with scaling analyses. The enhancement in 
AMLO permeation was found to be in the order of 1.5mm ADM ≥ PM-3 > 1.2mm ADM > 
0.6mm ADM ≥PM-1 > Passive. The study suggests that MN application enhances the AMLO 
transdermal permeation and the geometrical parameters of MNs play an important role in the 
degree of such enhancement. 
 
Keywords: Amlodipine, Histological examination, Microneedle geometry, Scaling analyses, 
Transdermal permeation. 
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INTRODUCTION 
Delivering medicines to the systemic circulation through the skin is considered as a good 
alternative to conventional oral or parenteral routes of administration owing to the advantages 
like lack of pain, ease of administration, etc., thus improving patient compliance; while 
improving the overall therapeutic gain of the drug by bypassing the gastrointestinal tract, 
avoiding hepatic first pass metabolism, maintaining a constant and prolonged drug level in 
plasma, etc [1, 2]. These advantages make transdermal drug delivery particularly interesting 
and beneficial in the management of conditions like hypertension that impose the burden of 
repeat dosage and chronic administration of medicines via conventional routes. 
Hypertension, reputed as ‘the silent killer’, is affecting about 70 million people and accounts 
for 9.4 million deaths worldwide every year. It is arguably the most important risk factor for 
coronary heart disease and stroke [3, 4]. Amlodipine besylate (AMLO) is a calcium channel 
blocker used to treat hypertension and associated cardiovascular diseases. On oral 
administration, it undergoes extensive first pass metabolism and has an oral bioavailability 
(BA) of only 60-65% and is also associated with several side effects such as nausea, stomach 
pain, flushing, etc., [5, 6]. Hence, transdermal delivery of AMLO may alleviate the side 
effects, improve the BA and overall patient compliance towards medication. However, 
AMLO, with an n-octanol/water log P values of 0.65,1.33 and was reported to be too 
hydrophilic to permeate through skin at significant rates without the application of any 
transdermal permeation enhancement technique [7]. 
Several attempts have been made to overcome the excellent barrier properties of the stratum 
corneum, the outer most layer of skin, to enhance transdermal delivery of AMLO. Use of 
different chemical permeation enhancers like sodium lauryl sulphate, Alcohol, propylene 
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glycol, etc. was reported to increase the transdermal permeation of AMLO to certain extent, 
however, not clinically significant [7-10].  
Microneedles (MN), a novel transdermal permeation enhancement technique, are minimally 
invasive and potentially painless method of overcoming the barrier properties of skin for 
enhanced delivery of drugs [11].  This technique has many advantages when compared to 
hypodermic injection, is believed to make conduits of micrometer dimensions in skin layers 
in the epidermal layers (especially, SC) and thus believed to enhance the transdermal 
permeation of drugs [12]. MNs are known to improve the permeation of drug molecules, 
including macromolecules like insulin, growth hormone, etc [13-15].  
Monika et al., (2013), studied the effect of stainless steel solid microneedles and microneedle 
rollers on percutaneous penetration of verapamil hydrochloride and amlodipine besylate [16]. 
The study inferred a statistically significant enhancement in transdermal permeation of both 
molecules following MN application. Even though two types of MN devices viz. array and 
rollers were employed in the study, no further evaluation was carried out to determine their 
relative efficiency on permeation enhancement of AMLO. Transdermal permeation 
enhancement of drugs using microneedle technology is a complex phenomenon and it has 
been reported in the literature that several geometric parameters of MNs like shape, 
dimensions, density of MN on the device and type etc. play important roles in enhancing the 
transdermal permeation of drugs [17]. There is also interplay of the effect of these variables 
and, as such, their effects on the permeation of a drug molecule are generally non-intuitive. 
As a result, their effects are best studied for specific case [17, 18].  
Motivated by this idea, the present study was designed as a systematic approach to explore 
the effect of MN geometry on the extent of AMLO transdermal permeation enhancement. 
Two types of MN devices viz. commercially available AdminPatch® arrays (ADM) (0.6, 1.2 
and 1.5 mm length) and laboratory fabricated polymeric MN arrays (PM) (0.6 mm length) of 
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different MN densities were employed in this investigation (Fig. 1).  A number of different 
techniques like etching, lithography and moulding were discussed widely in the literature for 
the manufacture of MNs of different dimensions (100-1800 μm in length), shapes with 
different materials (plastics, silicon, ceramics, metals, etc.). Injection moulding offers several 
advantages in terms of ease of scalability for bulk manufacture, range of materials and good 
reproducibility [19].  In this study, micro-injection moulding was employed for fabrication of 
the polymeric MN arrays (PM) using PEEK LT-3 (polyether ether ketone) as reported in 
previous paper [20]. 
Surface visualization and histological evaluation of skin samples were carried out to confirm 
and to study formation miroconduits by application of either types of MN devices.  
Moreover, the obtained AMLO permeation data was subjected to mathematical treatment 
using scaling analyses to obtain correlations between dimensionless parameters like amount 
of AMLO permeated (Ct/Cs) and various variables of the study like surface area (Sa/L2) and 
thickness (h/L) of skin based on the principles of Buckingham π theorem as described in a 
previous papers in order to gain insights into the phenomenon of AMLO transport behaviour 
and distribution in the skin layers [21, 22]. 
 
MATERIALS AND METHODS 
Materials  
AdminPatch® MN arrays were purchased from AdminMed, Sunnyvale, U.S.A. Amlodipine 
besylate (AMLO) was obtained from Arene Life Sciences, Hyderabad, India; Sodium 
chloride, isopropyl alcohol, propylene glycol and 1%w/v Safranin solution from Loba 
Chemie, Mumbai, India; Formic acid, acetonitrile, methanol and HPLC water from Merck 
Specialities Pvt. Ltd, Mumbai, India; Haematoxylin and Eosin stain from Sigma-Aldrich, 
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Bengaluru, India. All the reagents and chemicals used in the study were of HPLC grade.  Pig 
ear skin was obtained from local abattoirs. 
Fabrication of Polymeric MN (PM) 
MN array components consisted of 25 conical needles, each 0.6 mm in length with a base 
diameter of 0.3 mm, in a 5 x 5 array over a 0.5 x 0.5 cm2 area, supported by a circular 
substrate of diameter 17.5 mm and thickness 0.5 mm. Moulding of these components was 
performed using a Wittmann-Battenfeld Micro-Power 15 micro-injection moulding machine 
as shown in Fig. 2A. This machine offers a high repeatability, accurate dosing, clean room 
facility, and robotic component handling which is ideal for the bulk manufacture of MNs.  
The MN mould insert (Fig. 2B) was made out of Stavax ESR (Bohler-Uddeholm Corp, Elgin, 
USA). Sink electrical discharge machining (EDM) was used to create negative MN features 
into the insert and was outsourced to Isometric tool and design Inc. (New Richmond, USA).  
The polymer used for this study is PEEK (Polyetheretherketone) LT-3 grade material, which 
is an FDA-approved semi-crystalline biomaterial manufactured by Invibio Inc, Lancashire, 
UK and is widely employed for medical use. The attractive characteristics of PEEK LT-3 for 
this application include its excellent processability, dimensional stability, mechanical 
strength, chemical resistance and resistance to gamma and ethylene oxide sterilisation 
methods. To ensure the moisture content of the material was suitable for processing, the 
material was dried at a temperature of 150 ºC for 4 hours prior to moulding. 
Moulding trials were performed to optimise the process parameters based on measurement of 
the needle dimensions and substrate flatness.  The optimised parameters for the moulding of 
PM are shown Table 1.  Once the process was stabilised, samples were collected for the 
subsequent experimental work. 
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MN dimensional evaluation 
Scanning electron microscope: 
A Hitachi TM-3000 table-top Scanning Electron Microscope was used for analysis of the MN 
insert and needle geometry. The Hitachi TM-3000 has a magnification from 15X to 30000X, 
sample chamber of 700 mm diameter and 50 mm thickness. It features 5 kV, 15 kV and 
analysis observation modes. Because of the high aspect ratio and low contrast of the MNs, 
analysis mode was used for imaging. The major advantage of using TM 3000 SEM was it 
works under low vacuum and does not need specimen coating. 
Confocal laser microscope: 
It is very important to measure the tip radius and height of the MNs and the most common 
methods used are optical or electron microscopy. Because of its steep and complex structures, 
a 3D image analysis gives a better measurement of the needle geometry and quality control. 
In this study an Olympus vertical scanning laser confocal microscope LEXT OLS 4000 was 
used to accurately measure the tip radius and height of MN arrays. 
The device offers a broad magnification range from 108X to 17280X and the exact 3D 
reconstruction of the MNs. The confocal laser microscope LEXT scans the surfaces with a 
laser beam with the wavelength of 405 nm thus allowing submicron visualization of material 
and component surfaces with the resolution of down to 0.10 µm. Measurements were taken 
with the 20X lens using the wide range stitching feature with 20 percent overlap to produce a 
measurement area of 5mm x 5mm. A five level brightness switch was enabled to accurately 
illuminate the specimen. 
Atomic force microscope: 
The most important feature of the MN is that the tip has to be sharp in order to effectively 
pierce the skin. So as to confirm the measurements made from confocal laser microscope, 
AFM (MFP-3D Asylum Research Santa Barbara, USA) was used to measure the tip radius of 
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the MNs. All AFM scans were made using an MFP-3D scanner from Asylum Research, 
Santa Barbara, USA. Silicon nitride cantilever tips (Applied Nanostructures, Santa Clara, 
USA) with a tip radius of 15 nm and spring constant of 0.3 Nm were used. Images were 
interpreted using integrated MFP-3D™ Igor software (USA). Errors in the piezo-linearity 
were corrected for by using zero and first order flattening. 
 
HPLC method  
RP-HPLC-PDA method was developed specifically for the analysis of AMLO in the 
transdermal permeation samples.  A Shimadzu Prominence HPLC system provided with 
DGU-20A3 degasser, LC-20AD binary pumps, SIL-20AHT auto sampler and SPD-M20A 
PDA detector was used for analysis of the samples.  Data acquisition was carried out using 
LC solutions software.  Separation was achieved on an Inertsil ODS column (250 × 4.6 mm; 
5 µm).  The mobile phase comprised of 0.01% v/v formic acid : acetonitril 70:30 (v/v) at a 
flow rate of 1.2 mL/min with an injection volume of 20 µL and the eluents were monitored at 
238 nm.  The developed method was validated as per ICH guidelines. 
 
Solubility studies  
The solubility of AMLO was studied in different vehicle combinations of propylene glycol 
(PG), polyethylene glycol-400 (PEG), and saline (S) at 70:30, 80:20 and 90:10% v/v ratios.  
To each vehicle system, excess amount of AMLO was added and vortexed for 1 min in order 
to obtain a saturated solution and the solutions were equilibrated at 37°C in an orbital shaker 
for 24 h.  After equilibration, the samples were centrifuged at 3000 rpm for 10 min and 
filtered through a nylon syringe filter (0.45µm) and all the samples were appropriately diluted 
and analysed by HPLC method. 
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Skin Preparation 
Pig ears were collected from the local abattoirs immediately after animals were killed by 
electric current.  The ears were transported to the laboratory in a cooling box without 
previous treatment.  In the laboratory, the pig ears were washed carefully with distilled water 
and the hair was removed from the external part of pig ear using an electrical hair clipper.  
Carefully the full-thickness skin from the external part of the pig ear was separated from 
underlying cartilage using a scalpel and excess fat underlying the skin was removed to a 
thickness of 1.2mm was employed for the in vitro transdermal permeation studies.  The 
dermis side was wiped with isopropyl alcohol to remove the residual adhering fat.  Processed 
skin samples were individually wrapped in plastic bags without air entrapment and stored in a 
deep freezer at -20°C until further use. 
  
Application of MNs on skin samples 
Prior to the in vitro skin permeation experiments, the skin samples were allowed to be 
brought to room temperature and then the skin surface was carefully washed with saline.  
Two types of MN devices viz, ADM (0.6, 1.2 and 1.5 mm) and PM (0.6mm) were used to 
poke the skin surface under thumb pressure.   In the case of PM, both single (PM-1) and triple 
(PM-3) insertions at different places within a 1.77cm2 skin area (PM-3) were made in order to 
maintain the MN density closer to ADM of 0.6mm length as shown in Fig. 1.  The MNs were 
periodically checked during this process for potential damage using a stereomicroscope. 
 
Surface visualization and histological examination of the skin samples  
To visually confirm the disruption of skin layers by the MNs, the arrays were pressed over 
the pig ear skin under thumb pressure and held for 1 min.  Then the skin was stained with 
safranin dye (1% w/v in water) and wiped with isopropanol cotton swabs for the 
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identification of the microconduits formed.  In the case of the histological studies, the skin 
section samples with and without MN treatments were prepared after staining with 
haematoxylin and eosin for visualization of skin layers and to display a clear indentation by 
MN penetration.  The sections were observed under a microscope (Olympus; Noida, India).  
The width and depth of microconduits formed were also calculated in triplicate (n = 3 skin 
samples for each MN) with the help of Toup View 3.2 Software (Irwin, U.S.A).  For control, 
skin samples without MN treatment were also prepared. 
 
In Vitro Skin Permeation Studies 
The in vitro transdermal permeation studies were performed using a vertical type Franz 
diffusion cell apparatus fitted with a water circulation system, a water heater and an eight 
stage magnetic stirrer (Orchid Scientifics, Nasik, India). Franz diffusion cells with an 
effective diffusion area of 1.77 cm2 and a receptor volume of around 14 mL were used.  
Saline was used as the receptor fluid.  Pig ear skin was mounted between the donor and 
receptor cells with the SC facing towards the donor cell.  The receptor medium was stirred 
for uniform drug distribution at a speed of 600 rpm throughout the experiment.  Care was 
taken to prevent the entrapment of air bubbles at the interface of the skin (dermis) and the 
receptor solution.  The surface of the skin was maintained at 32°C using a circulating water 
bath. After equilibration, 500 µL of donor solutions containing excess amount of AMLO 
were applied on to the skin (in the donor compartment).  Samples (500 µL) were withdrawn 
from the receptor fluid at six hour increments up to 48 hours and replaced with the fresh 
saline to maintain a constant volume.  All the samples were stored at 4°C, prior to the HPLC 
analysis. 
The cumulative permeation profiles were plotted for the cumulative amount of drug 
permeated (nmoL/cm2) as a function of time, for untreated and microneedle treated skin.  The 
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flux values and the respective lag times were obtained from the slope and the X-intercept of 
the steady state portion of the cumulative permeation profiles.  Apparent permeability and 
diffusion coefficient values were computed from Fick’s first law of diffusion: 
 
Js is the steady-state flux (nmoL/cm²/hr), M is the cumulative amount of drug permeating the 
skin (nmoL/cm²), A is the area of the skin (1.77 cm2), Kp is the apparent permeability 
coefficient (cm/hr), and ΔC is the difference in concentrations of AMLO in the donor and 
receiver. Sink conditions were maintained in the receiver throughout the experiment and 
hence ΔC was approximated to be the drug concentration in the donor compartment.  
Enhancement ratios were also computed to evaluate the relative efficiency of different MNs 
on the AMLO skin permeation enhancement. The enhancement ratios were calculated as 
follows: 
𝐸𝐸𝐸𝐸ℎ𝑎𝑎𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝐸𝐸𝑎𝑎 𝑅𝑅𝑎𝑎𝑎𝑎𝑅𝑅𝑅𝑅 =  Cumulative amount or Flux obtained after MN applicationCumulative amount or Flux obtained from passive studies 
                     
AMLO content in skin 
After the completion of the permeation studies, skin samples were studied for drug 
disposition.  The skin tissue exposed to the donor solution was cut with a scalpel and washed 
with filtered water and blotted with a paper towel in order to remove the drug which had 
adhered to the surface.  Then skin was minced with a scalpel, and placed in a pre-weighed 
vial.   The drug was extracted from the skin by equilibrating with 5 mL of acetonitrile at 32°C 
in an orbital shaker.  The solutions were then analyzed by HPLC to determine the AMLO 
content. 
 
CKJ
dt
dM
A ps
∆==




1
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Scaling analyses 
Dimensionless correlations between the amount of AMLO permeated (Ct/Cs) and other 
variables such as the thickness (h/L) and the surface area (Sa/L2) of the skin were made in 
order to gain insights into the overall phenomenon of AMLO transdermal permeation 
enhancement by MN application.  The scaling analyses were carried out based on the 
principles of the Buckingham π theorem where it is defined that the dimensionless 
concentration of a drug, which permeates through skin, can be defined in terms of key non-
dimensional parameters (e.g., MN lengths) using the procedures described in previous papers 
[21, 22].   
Eq.1 describes the relationship of all the model parameters used for such analyses (Table 2). 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 𝐾𝐾 �𝑆𝑆𝑎𝑎𝐿𝐿4𝐾𝐾𝑒𝑒
𝑉𝑉𝑑𝑑ℎ𝐷𝐷
�
𝑛𝑛
   (1) 
Where, ‘K’ is a dimensionless constant and ‘n’ is an unknown power; Ct and Cs are the 
amount of AMLO permeated at a given time t (48 h) and the amount of drug loaded in the 
donor compartment for diffusion (surface concentration on skin); Sa is the surface area of 
skin available for diffusion; L is the length of microneedles; Ke and Vd are the first order 
elimination constant and the volume of receptor fluid; ‘h’ is the thickness of skin and D is the 
diffusion coefficient of AMLO in skin. 
Using Eq.1, the correlations between the dimensionless AMLO concentration (Ct/Cs) against 
the dimensionless parameters of the study (h/L and Sa/L2) have been established considering 
that all other variables remain unchanged. 
 
Statistical analysis of the data 
Results of the experimental data were subjected to statistical analysis by one way ANOVA 
(using Fischer’s LSD post hoc test) using SYSTAT 13 software (Systat Software Inc., San 
Jose, USA).  Results with a p value of less than 0.05 were considered to have statistically 
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significant variance.  Mean of replicate measurements (n = 3) with corresponding standard 
deviation (SD) was used to represent the data and to plot the graphs. 
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RESULTS AND DISCUSSION 
Fabrication and characterization of PM 
Polymeric MN arrays (PM) were fabricated using (PEEK)-LT3 (polyether ether ketone) 
using micro-injection moulding technique, with 25 MN on each array (MN density) and the 
array base thickness of 300 µm.  The dimensions of PM, determined using a 3D confocal 
imaging (Fig. 3A) and scanning electron microscopy (SEM) (Fig. 3B), were found to be 556 
± 30 µm in height with a tip radius of 32 ± 8 µm, with a base thickness of 300 µm and MN 
interspacing of approximately 1 mm at the base. 
For better comparison and understanding of the difference in the shape/design between PM 
and ADM devices, 3D confocal images of 0.6 mm ADM were given in Fig. 3C.  Also the 
difference in base thickness among the devices can be clearly observed from Fig. 1. The 
various geometry parameters of both types of MN devices were given in Table 3. 
The dimensions of the PM were found to be consistent and repeatable with good tip shape, 
confirming the complete filling of the PEEK into the MN insert cavity under the maintained 
processing conditions (Table 1) and the technique used is reliable for the bulk manufacture of 
PMs. Compression tests of PM on a steel plate using Bose Electroforce 3100 instrument with 
a 225 N load cell and Wintest® software (Bose, MN, USA) revealed that the PMs were able 
to withstand compression forces of up to 8 N [20].   
Analytical Method 
A rapid and sensitive HPLC-PDA method was developed for the selective quantification of 
AMLO in transdermal permeation studies.  Under the developed LC conditions, AMLO 
eluted at 3.9 min with good peak shape.  Also, the specificity of the method to AMLO was 
demonstrated by the UV spectrum and the peak purity index curves.  The method was 
validated as per ICH guidelines and complied with all the requirements. The method was 
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successfully employed for the quantitative estimation of AMLO in various samples 
throughout the study. 
Solubility Studies 
Solubility studies for AMLO were performed with a view to select appropriate donor vehicle 
for conducting in vitro skin permeation studies.  PG:S and PEG:S combinations at 70:30, 
80:20 and 90:10 %v/v were studied for AMLO solubility.  The solubility data obtained was 
shown in Fig. 4. Solubility of AMLO was relatively higher in PG:S when compared with 
PEG:S combinations (p>0.05) (Fig. 4). The solubility of AMLO increased as the water 
content of the vehicle system increased, in the order 90:10<80:20<70:30 % v/v in both PG:S 
and PEG:S combinations. However, a significant difference was not observed among the 
vehicle combinations (p>0.05). PG:S at 70:30%v/v was selected for the AMLO in vitro skin 
permeation studies.  
Surface visualization and histological examination of skin samples 
In order to visually confirm the ability of disruption of skin layers by MNs, the arrays were 
pressed over the pig ear skin under thumb pressure and held for 1 min and the skin samples 
were stained with safranin (1%w/v).  The skin samples showed clear distinctions in the 
number of the microconduits formed as per the length and density of MNs in ADM and PM 
devices (Fig. 5).  
Histological section images of skin treated with MNs were shown in Fig. 6.  From the 
images, the stratum corneum disruption and the formation of microconduits across skin layers 
was clearly evident.  The average penetration depth (vertical)  (n = 3) of the MNs was found 
to be 180.26 ± 30.39, 400.85 ± 20.83, 478.48 ± 67.72 and 338.20 ± 22.66 µm for ADM (0.6, 
1.2, 1.5 mm) and PM, respectively. The average penetration depth (vertical) was about 25-
35% for ADM and 55-60% for the PM MN lengths (Fig. 6). Even though the length of the 
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MNs differ in ADM, the percentage of MN penetration is almost same, which is an indication 
of uniformity in thumb pressure under which MNs were applied at different times. 
With the ADM devices, as the length of the MNs increased the penetration depth also 
increased. However, the microconduits were found to be wider and deeper with PM when 
compared to ADM of similar lengths i.e. 0.6 mm. These differences in the efficiency of 
creating microconduits in skin layers between the two types of MN devices (ADM and PM) 
may be attributed to the differences in geometry parameters like shape, design and type of 
fabricating material. Regarding the shape/design, PM being conical (3D) in shape, the 
microconduits formed by PM were wider, while that with ADM looks merely like a cut on 
the skin (2D) as the arrays of ADM are low in thickness (2D) (Fig. 3).  Furthermore, owing to 
the sturdy and thick base (when compared to ADM) that supports the solid PM (Fig. 1), the 
effective resistance (because of the viscoelastic nature) of the skin during application of 
arrays may be less for PM, while the ADM might have experienced greater resistance which 
is because of their thin base and array design [23], resulting in a relatively shallow 
penetration with similar MN lengths (0.6 mm ADM). 
In vitro permeation studies  
The comparative in vitro pig ear skin permeation profiles of AMLO without and with MN 
application were shown in Fig. 7.  Various AMLO permeation parameters viz. cumulative 
amount permeated at the end of 48h, steady state flux, lag time, permeability and diffusion 
coefficients without and with microneedle treatment were given in Table 4. 
Significant enhancement in AMLO permeation was observed after MNs application onto the 
skin (p<0.05) when compared to passive permeation studies (Fig. 7). A 2.00, 3.56 and 6.84 
fold increase in the cumulative amount (48 h) of AMLO permeated was observed with 0.6, 
1.2 and 1.5 mm ADM treatments, respectively, when compared to passive permeation 
amount.  A similar trend was observed with other permeation parameters like permeability 
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and diffusion coefficient values (Table 4).  Significant reduction in the lag time was observed 
after application of 1.2 and 1.5 mm ADM when compared to that with passive permeation 
studies (p<0.05).   However, there is no statistically significant difference between passive 
and 0.6mm and 1.2mm ADM treatments in terms of lag time (p>0.05).  
The AMLO flux values were found to be in the order of 1.5mm > 1.2mm > 0.6mm > passive 
with ADM treatments (p<0.05).  A 5.29 fold increase in AMLO flux was observed with the 
1.5 mm when compared to passive studies. It was observed that the enhancement of AMLO 
permeation was only marginal with the application of 0.6 mm ADM when compared to 
passive studies (Fig. 7). This may be due to the fact that the skin disruption/penetration 
caused by 0.6 mm ADM was less as supported by histological section images (Fig. 6).  
 Moreover, the AMLO permeation was significantly higher with 1.5 mm ADM when 
compared to 0.6 and 1.2 mm ADM (p<0.05) even though the density of MNs is low, which is 
may be because of longer needle lengths which intern resulted in deeper skin penetration. 
With the PM application, a 1.63 and 6.11 fold increase in the cumulative amount (48 h) of 
AMLO permeated was observed with PM-1 and PM-3 treatments respectively, when 
compared to passive permeation amounts.  The lag times were found to be significantly lower 
for PM-3 when compared to passive and PM-1 treatments (p<0.05). The AMLO flux values 
were found to be in the order of PM-3 > PM-1 > passive treatments (p<0.05). A 5.23 and 
1.46 fold increase in AMLO flux was observed with the PM-3 and PM-1 respectively, when 
compared to passive studies. A similar trend was observed with other permeation parameters 
like permeability and diffusion coefficient values (Table 4) with both the PM treatments. 
Even though, the skin penetration by PM device (with 0.6mm array) was significantly greater 
when compared to 0.6 mm ADM, the overall permeation enhancement in terms of cumulative 
amount permeated etc. achieved with PM-1 was found to be closer to those of 0.6 mm ADM 
(p>0.05).  This may be because the needle density of 0.6 mm ADM was greater when 
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compared to PM-1 (Table 3), which may have compensated the variation in the extent of skin 
penetration among these MNs, and thus no significant variation in overall permeation 
enhancement was observed among these two MNs (p>0.05).   
In case of the PM, a single application of array didn’t cover the 1.77cm2 surface area of the 
skin and hence in order to maintain the MN density closer to ADM of 0.6mm length the 
arrays were applied three times at different places within a 1.77cm2 skin area (PM-3) as 
shown in Fig. 1.  As the needle density was increased with PM-3, the AMLO transdermal 
permeation increased markedly and was similar to that obtained with 1.5 mm ADM (p>0.05). 
Moreover, it is intriguing to note although the needle density PM-3 (75 MNs) was 
significantly greater when compared to 1.5 mm ADM (31 MNs) the overall AMLO 
permeation enhancement was considerably greater with 1.5 mm ADM with significantly 
shorter lag times (p<0.05), which may be because of deeper (vertical) penetration into skin. 
Even though the depth of the penetration was significantly lower with PM when compared to 
1.5 mm ADM, the comparable permeation enhancement by PM-3 is may be because of 
higher needle density and also wider microconduits formed as evidenced by histological 
section images (Fig. 6). 
The enhancement in AMLO permeation was found to be in the order of 1.5mm ADM ≥ PM-3 
> 1.2mm ADM > 0.6mm ADM ≥PM-1 > Passive.  Even though, no correlation of AMLO 
skin content was observed with different MN treatments, significantly higher amounts of 
AMLO were found to be distributed in skin layers at the end of 48h with MN treated studies 
and is an indication of potential AMLO skin deposition.   
Overall, the transdermal permeation enhancement of AMLO by MN application is a complex 
phenomenon and the permeation enhancement is dependent on the several aspects of the MN 
geometry like the shape/design, length and density etc. 
Scaling analyses 
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Using scaling analyses, correlations were developed for ADM MNs (same type but differing 
in length) between the dimensionless parameters, namely the amount of AMLO permeated 
(Ct/Cs) and skin thickness (h/L) and surface area of skin (Sa/L2) in order to derive a better 
understanding on the effect of specific geometry parameters of MN, like length (L), on 
overall permeation enhancement by MNs of same design (ADM) (Fig. 8 A, B respectively) 
[21, 22].  Eqs. 2 and 3 describe such relationships among the considered parameters within 
the given range.  These correlations were determined for given thickness and surface area of 
skin while the MN length varies (0.6, 1.2 and 1.5 mm). 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 5.957𝑥𝑥10−3 �ℎ
𝐿𝐿
�
−1.2206
 for 0.8 ≤ ℎ
𝐿𝐿
 ≤ 2  ---- (2) 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 0.112 �𝑆𝑆𝑎𝑎
𝐿𝐿2
�  −0.6103  for 78.5 ≤ 𝑆𝑆𝑎𝑎
𝐿𝐿2
 ≤ 491.5 ---- (3) 
Good correlations (R2>0.89) were observed between the dimensionless parameters (Ct/Cs vs 
h/L and Ct/Cs vs Sa/L2) (Fig. 8). These correlations can be used to predict the amount of 
AMLO permeated (Ct/Cs) with high accuracy for other MN lengths in the range of 0.6-1.5 
mm with similar design as ADM. 
CONCLUSION 
Transdermal permeation enhancement of AMLO by MN application and the effects of 
various geometry parameters on the degree of such enhancement was studied in this 
investigation using two types of MN devices (ADM and PM). A significant enhancement in 
the transdermal permeation of AMLO across pig ear skin was observed with application of 
MNs.  It was further noted that the type/shape, density and more importantly, the length of 
MNs (depth of penetration into skin) play a crucial role in the overall permeation 
enhancement of AMLO using this technique.   It may be inferred that the transdermal 
delivery of AMLO in a painless and non-invasive manner may by possible using MN 
applications. However, the observed lag times and transdermal flux values suggest that a still 
higher enhancement in permeation may be required in order to achieve clinically significant 
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levels of the AMLO more rapidly after application of the transdermal system. This 
investigation can form a basis for further studies (in vivo) and for optimization of various MN 
parameters to achieve successful delivery of AMLO via. MN assisted transdermal delivery 
systems and in continuation to this study further development on AMLO containing MNs is 
of good choice. 
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CAPTIONS FOR FIGURES 
Fig. 1: Different MNs used in the study 
Fig. 2: (A) Battenfeld micro-power 15 moulding machine; (B) 3D drawing of the 
microneedle insert 
Fig. 3: (A) 3D confocal image of (a) front view of the PEEK MN array (b) Single MN of 
PEEK (c) line measurement of the PM array; (B) SEM image of (a) MN array of PEEK (b) 
top view of the needle (c) Single MN of PEEK; (C) 3D confocal image of 0.6 mm ADM 
showing its design parameters 
Fig. 4: Solubility Data of AMLO in PG:S and PEG:S Solvent Systems 
Fig. 5: Surface images of stained skin without and with MN treatment 
Fig. 6: Penetration depth calculation of ADM and PM in skin (ToupView® screenshot) 
Fig. 7: Comparative in vitro skin permeation profiles of AMLO from passive and MN 
treatments 
Fig. 8: Scaling relationship of different dimensionless groups for permeation of AMLO - (A) 
Effects of dimensionless length of MNs; (B) Effects of dimensionless surface area for 
diffusion 
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TABLES 
 
Table 1. Micro-injection moulding parameters 
Parameter PEEK 
Melt temperature (°C) 400 
Maximum injection velocity 
(mm/s) 
750 
Clamping force (kN) 50 
Holding pressure (bars) 600 
Mould base temperature (°C) 210 
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Table 2. Model parameters for dimensional scaling analyses of the data 
Parameter Value 
Duration for medication: tm 48 h 
Surface area of skin exposed: Sa 1.77 cm2 
Thickness of stratum corneum: hsc 0.002 cm 
Total Thickness of membrane (distance 
to blood vessel): h 
0.12 cm 
Effective skin thickness: he Variable 
Diffusion coefficient in viable skin: D Variable 
Volume of Fluid in Receptor 
Compartment (distribution): Vd 
14 mL 
Skin surface/Donor concentration: Cs 
Saturated Solution was charged 
as the donor solution 
Microneedle length: L  0.06, 0.12 and 0.15 cm 
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Table 3. Different geometry parameters of MNs used in the study  
Parameter ADM* PM  0.6 1.2 1.5 
Length (µm) 600 1200 1500 560 ± 30 
Number of MNs (1.77 cm2) 187 41 31 25 
Shape Flat (2D) Conical (3D) 
Thickness of each MN (µm) 78 (uniform till tip)** 300 (~30 at tip) 
Thickness of array base (µm) 100-200** 300 
Material Medical grade stainless steel (SS 316L) 
PEEK LT-3 (polyether 
ether ketone) 
*values are from manufacturer23 
**the width and thickness of the MN and the base varies with length 
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Table 4. Permeation parameters of AMLO without and with MN treatments 
Skin 
treatment 
Permeation Parameters 
Cumulative 
amount permeated 
at 48h (nmoL/cm²) 
Steady state 
flux 
(nmoL/cm2/h) 
Lag Time (h) 
Permeability 
coefficient 
(x10-05) 
(cm/hr) 
Diffusion 
coefficient 
(x10-10)   
(cm2/sec) 
Skin Content 
(µg/g) 
Passive 293.069 ± 28.646 10.03 ± 1.33 19.12 ± 1.06 2.60 ± 0.34 8.68 ± 1.15 1351.55 ± 281.43 
0.6 ADM 586.181 ± 40.822 19.10 ± 2.10 17.33 ± 0.98 4.96 ± 0.54 16.53 ± 1.82 1652.22 ± 246.25 
1.2 ADM 1042.552 ± 174.023 29.96 ± 4.80 13.22 ± 1.03 7.78 ± 1.25 25.93 ± 4.16 1724.24 ± 165.22 
1.5 ADM 2005.307 ± 123.098 53.04 ± 4.43 10.02 ± 0.78 13.77 ± 1.15 45.91 ± 3.83 2197.20 ± 331.71 
PM-1 477.466 ± 64.229 14.65 ± 1.00 16.07 ± 2.18 3.81 ± 0.26 12.68 ± 0.87 1597.32 ± 95.23 
PM-3 1791.853 ± 165.519 52.44 ± 2.77 13.69 ± 1.34 13.62 ± 0.72 45.39 ± 2.40 1880.74 ± 151.62 
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